Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin Detemir vs Glargine as Add-on to OADs in Type 2 Diabetes
NCT00283751Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Mar 2003
- Primary completion
- Nov 2004
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
Phase 3, randomised, open-label trial of insulin detemir in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Glycosylated Hemoglobin A1c at 52 weeks. Started Mar 2003; status: completed.
02
Drugs
insulin detemir
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00283751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00283751.